| A | B |
|---|
| succinylcholine MOA | Depolarizing Relaxant Drugs |
| succinylcholine kinetics | extremely short duration of action due to its rapid hydrolysis by cholinesterases |
| succinylcholine identifies | dibucaine number; genetically abnormal variant of plasma cholinesterase |
| Dantrolene effects | reduces skeletal muscle strength by interfering with excitation-contraction coupling in the muscle fibers |
| Dantrolene MOA | interferes w/release of activator Ca+ through SR by binding RyR and blocking the opening |
| Dantrolene indications | treatment of malignant hyperthermia, reduces calcium release |
| cyclobenzaprine indications | relief of acute muscle spasm caused by local tissue trauma or muscle strains |
| cyclobenzaprine | ineffective in treating muscle spasm due to cerebral palsy or spinal cord injury |
| cyclobenzaprine effects | act primarily at the level of the brainstem, has antimuscarinic effects |
| baclofen | does not reduce overall muscle strength as much as dantrolene |
| baclofen MOA | exerts its spasmolytic activity at GABAB receptors |
| diazepam adverse affects | produces sedation at dose required to reduce muscle tone |
| diazepam MOA | acts at GABAA synapses |
| pyridostigmine and neostigmine | antagonize nondepolarizing neuromuscular blockade mainly by inhibition of acetylcholinesterase |
| administration of tubocurarine (aka: curare) | initially causes motor weakness, then skeletal muscles become flaccid and inexcitable to electrical stimulation |
| atracurium | intermediate-acting isoquinoline nondepolarizing muscle relaxant |
| Nondepolarizing Relaxant Drugs | atracurium, mivacurium |
| mivacurium adverse effects | can be associated with profound histamine release leading to hypotension, flushing, and bronchospasm |
| mivacurium | shortest DOA of all nondepolarizing muscle relaxants, but long onset |
| pancuronium | long-acting steroid-based non-depolarizing muscle relaxant |
| vecuronium | non-depolarizing intermediate-acting steroid muscle relaxant |
| malignant hyperthermia | hereditary impairment in the ability of the sarcoplasmic reticulum to sequester calcium |
| triggering agents, malignant hyperthermia | general anesthetics and neuromuscular blocking drugs |
| Succinylcholine is the only clinically useful depolarizing blocking drug | is the only clinically useful depolarizing blocking drug |
| Succinylcholine reacts with the nicotinic receptor to | open the channel and cause depolarization of the motor end plate |
| Because succinylcholine is not metabolized effectively at the synapse | results in state of depolarizing block and flaccid paralysis |
| neuromuscular blocking drugs makes it possible to achieve | adequate muscle relaxation w/o cardiorespiratory depressant effects produced by deep anesthesia |
| treatment for malignant hyperthermia | dantroline sodium |
| succinylcholine can trigger | malignant hyperthermia in predisposed patients |
